Inbec主治什么呢？

Suimeikai () is composed of three ingredients: DTG (DTG) + abacavir (ABC) + lamivudine (3TC). It is a compound treatment agent of integrase inhibitors and nucleoside drugs. Since the advent of the first anti-HIV drug zidovudine (AZT) in 1987, it has brought life hope to AIDS patients. Subsequently, more and more drugs have continued to appear, with more and more types of drugs, better and better therapeutic effects, and fewer and fewer side effects. At present, the world has basically entered the era of integrase inhibitor drugs, and continues to introduce new ones in the optimization of multi-drug combination regimens.

Inbec is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV).

Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or dose adjustments made, separate formulations of dolutegravir, abacavir, or lamivudine may be used. For adults and adolescents, the recommended dose of Inbec is one tablet once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Inbec because Inbec is a fixed-dose tablet and the dose cannot be reduced.

Patients whose creatinine clearance is less than 50mL/min are not recommended to take Inbec. Abacavir is mainly metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment, therefore, use of Inbec is not recommended unless deemed necessary.

Suimeikai () is a combination of three drugs that are equivalent. Both newly treated and previously treated patients have a high resistance barrier and are not likely to develop drug resistance. It is easy to take and only needs to be taken once a day without considering food effects. The drug has low side effects and is well tolerated. The discontinuation rate due to drug side effects is low. Metabolic pathways have few interactions with other drugs. Inbec has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients.